Abstract
The use of monthly intranasal mupirocin was associated with a significant reduction in the rate of methicillin-resistant Staphylococcus aureus transmission and Staphylococcus aureus invasive infection in a large neonatal intensive care unit. Resistance to mupirocin emerged over time, but it was rare and was not associated with adverse clinical outcomes.Infect Control Hosp Epidemiol 2018;39:741-745.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Intranasal
-
Anti-Bacterial Agents / therapeutic use*
-
Antibiotic Prophylaxis / methods
-
Cross Infection / epidemiology
-
Cross Infection / microbiology*
-
Cross Infection / prevention & control*
-
Female
-
Humans
-
Infant, Newborn
-
Intensive Care Units, Neonatal
-
Interrupted Time Series Analysis
-
Male
-
Methicillin-Resistant Staphylococcus aureus / drug effects*
-
Methicillin-Resistant Staphylococcus aureus / isolation & purification
-
Mupirocin
-
Regression Analysis
-
Staphylococcal Infections / epidemiology*
-
Staphylococcal Infections / prevention & control*
Substances
-
Anti-Bacterial Agents
-
Mupirocin